Phospholipid biosynthesis enzymes

Phospholipid biosynthesis enzymes represent a diverse group of proteins responsible for the de novo synthesis and remodeling of phospholipids, which are the primary structural components of biological membranes (Source: 1.1.1, 1.1.3). Key pathways include the Kennedy pathway—comprising the CDP-choline and CDP-ethanolamine branches—and the Lands cycle for lipid remodeling (Source: 1.2.1, 1.3.1). These enzymes, such as choline kinase alpha (CKα), CTP:phosphocholine cytidylyltransferase (CCT), and various acyltransferases, are critical for maintaining membrane integrity, facilitating signal transduction, and supporting rapid cellular proliferation (Source: 1.1.2, 1.2.3). In cancer, these enzymes are frequently upregulated to meet the high demand for membrane biogenesis, making them attractive targets for antineoplastic therapy (Source: 1.2.1, 1.2.5). Additionally, unique phospholipid biosynthetic pathways in bacteria, fungi, and parasites provide opportunities for selective antimicrobial and antiparasitic drug development (Source: 1.3.2, 1.5.1, 1.5.4). Pharmacological inhibition of these enzymes can lead to membrane instability, induction of endoplasmic reticulum stress, and apoptosis, offering a multi-faceted approach to treating metabolic, infectious, and malignant diseases (Source: 1.2.3, 1.4.1).

Other names

Kennedy pathway enzymesCDP-choline pathway enzymesCDP-ethanolamine pathway enzymesGlycerophospholipid biosynthetic enzymesLipid biosynthetic enzymes

Inhibition of de novo phospholipid synthesis, disruption of membrane integrity, induction of ER stress-mediated apoptosis, and inhibition of lipid remodeling.